Lacouture ME - Search Results

1

Dermatological adverse events from BRAF inhibitors: a growing problem.

Belum VR, Fischer A, Choi JN, Lacouture ME. Belum VR, et al. Among authors: lacouture me. Curr Oncol Rep. 2013 Jun;15(3):249-59. doi: 10.1007/s11912-013-0308-6. Curr Oncol Rep. 2013. PMID: 23463215 Review.

2

Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results.

Boone SL, Rademaker A, Liu D, Pfeiffer C, Mauro DJ, Lacouture ME. Boone SL, et al. Among authors: lacouture me. Oncology. 2007;72(3-4):152-9. doi: 10.1159/000112795. Epub 2007 Dec 21. Oncology. 2007. PMID: 18160805

3

A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group.

Lacouture ME, Maitland ML, Segaert S, Setser A, Baran R, Fox LP, Epstein JB, Barasch A, Einhorn L, Wagner L, West DP, Rapoport BL, Kris MG, Basch E, Eaby B, Kurtin S, Olsen EA, Chen A, Dancey JE, Trotti A. Lacouture ME, et al. Support Care Cancer. 2010 Apr;18(4):509-22. doi: 10.1007/s00520-009-0744-x. Epub 2010 Feb 10. Support Care Cancer. 2010. PMID: 20145956

4

Dermatologic toxicities of targeted anticancer therapies.

Balagula Y, Lacouture ME, Cotliar JA. Balagula Y, et al. Among authors: lacouture me. J Support Oncol. 2010 Jul-Aug;8(4):149-61. J Support Oncol. 2010. PMID: 20822032 Review.

5

Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886).

Balagula Y, Barth Huston K, Busam KJ, Lacouture ME, Chapman PB, Myskowski PL. Balagula Y, et al. Among authors: lacouture me. Invest New Drugs. 2011 Oct;29(5):1114-21. doi: 10.1007/s10637-010-9567-3. Epub 2010 Oct 27. Invest New Drugs. 2011. PMID: 20978926 Free PMC article.

6

Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors.

Balagula Y, Garbe C, Myskowski PL, Hauschild A, Rapoport BL, Boers-Doets CB, Lacouture ME. Balagula Y, et al. Among authors: lacouture me. Int J Dermatol. 2011 Feb;50(2):129-46. doi: 10.1111/j.1365-4632.2010.04791.x. Int J Dermatol. 2011. PMID: 21244375 Review.

7

Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.

Wu PA, Balagula Y, Lacouture ME, Anadkat MJ. Wu PA, et al. Among authors: lacouture me. Curr Opin Oncol. 2011 Jul;23(4):343-51. doi: 10.1097/CCO.0b013e3283474063. Curr Opin Oncol. 2011. PMID: 21537180 Review.

8

The emergence of supportive oncodermatology: the study of dermatologic adverse events to cancer therapies.

Balagula Y, Rosen ST, Lacouture ME. Balagula Y, et al. Among authors: lacouture me. J Am Acad Dermatol. 2011 Sep;65(3):624-635. doi: 10.1016/j.jaad.2010.06.051. Epub 2011 Jul 20. J Am Acad Dermatol. 2011. PMID: 21777992 Review.

9

Induction of cutaneous squamous cell carcinomas by RAF inhibitors: cause for concern?

Lacouture ME, O'Reilly K, Rosen N, Solit DB. Lacouture ME, et al. J Clin Oncol. 2012 Jan 20;30(3):329-30. doi: 10.1200/JCO.2011.38.2895. Epub 2011 Nov 7. J Clin Oncol. 2012. PMID: 22067405 No abstract available.

10

Rash to the mTOR inhibitor everolimus: systematic review and meta-analysis.

Ramirez-Fort MK, Case EC, Rosen AC, Cerci FB, Wu S, Lacouture ME. Ramirez-Fort MK, et al. Among authors: lacouture me. Am J Clin Oncol. 2014 Jun;37(3):266-71. doi: 10.1097/COC.0b013e318277d62f. Am J Clin Oncol. 2014. PMID: 23241507 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

322 results

Search Page

Filters